BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Cammà C, Colombo M; SOFIA (SOraFenib Italian Assessment) study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011;54:2055-63. [PMID: 21898496 DOI: 10.1002/hep.24644] [Cited by in Crossref: 256] [Cited by in F6Publishing: 249] [Article Influence: 23.3] [Reference Citation Analysis]
Number Citing Articles
1 Nomura T, Tani J, Deguchi A, Nakahara M, Oura K, Tadokoro T, Fujita K, Mimura S, Sakamoto T, Morishita A, Yoneyama H, Kobara H, Sanomura T, Nishiyama Y, Okano K, Suzuki Y, Takahashi S, Shibata T, Tsutsui K, Himoto T, Masaki T. Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion. Mol Clin Oncol 2019;11:447-54. [PMID: 31602300 DOI: 10.3892/mco.2019.1920] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitsu H. The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. PLoS One 2016;11:e0146456. [PMID: 26745625 DOI: 10.1371/journal.pone.0146456] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
3 Labeur TA, Achterbergh R, Takkenberg B, Van Delden O, Mathôt R, Klümpen HJ. Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study. Oncologist 2020;25:e1274-9. [PMID: 31645371 DOI: 10.1634/theoncologist.2019-0718] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
4 Dituri F, Mazzocca A, Peidro FJ, Papappicco P, Fabregat I, De Santis F, Paradiso A, Sabba C, Giannelli G. Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II. PLoS One. 2013;8:e67109. [PMID: 23826206 DOI: 10.1371/journal.pone.0067109] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 6.7] [Reference Citation Analysis]
5 Plaz Torres MC, Lai Q, Piscaglia F, Caturelli E, Cabibbo G, Biasini E, Pelizzaro F, Marra F, Trevisani F, Giannini EG. Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. J Clin Med 2021;10:3201. [PMID: 34361985 DOI: 10.3390/jcm10153201] [Reference Citation Analysis]
6 Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599-616. [PMID: 30061739 DOI: 10.1038/s41571-018-0073-4] [Cited by in Crossref: 482] [Cited by in F6Publishing: 494] [Article Influence: 160.7] [Reference Citation Analysis]
7 Alghamdi MA, Amaro CP, Lee-Ying R, Sim HW, Samwi H, Chan KK, Knox JJ, Ko YJ, Swiha M, Batuyong E, Romagnino A, Cheung WY, Tam VC; Hepatocellular Carcinoma - Cancer Health Outcomes Research Database (HCC - CHORD) Consortium. Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database. Cancer Med 2020;9:4918-28. [PMID: 32529797 DOI: 10.1002/cam4.3228] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Rimini M, Shimose S, Lonardi S, Tada T, Masi G, Iwamoto H, Lai E, Burgio V, Hiraoka A, Ishikawa T, Soldà C, Shirono T, Vivaldi C, Takaguchi K, Shimada N, Astara G, Koga H, Nouso K, Joko K, Torimura T, Hiasa Y, Salani F, Scartozzi M, Cascinu S, Casadei-Gardini A. Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study. Hepatol Res 2021;51:1229-41. [PMID: 34591334 DOI: 10.1111/hepr.13718] [Reference Citation Analysis]
9 Forner A, Díaz-gonzález Á, Liccioni A, Vilana R. Prognosis prediction and staging. Best Practice & Research Clinical Gastroenterology 2014;28:855-65. [DOI: 10.1016/j.bpg.2014.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
10 Celsa C, Giuffrida P, Giacchetto CM, Stornello C, Rancatore G, Grova M, Ricciardi MR, Rizzo S, Cammà C, Cabibbo G. Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. Liver Cancer International 2021;2:82-95. [DOI: 10.1002/lci2.38] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012;10:354-362. [PMID: 22083023 DOI: 10.1016/j.cgh.2011.11.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
12 Trevisani F, Brandi G, Garuti F, Barbera MA, Tortora R, Casadei Gardini A, Granito A, Tovoli F, De Lorenzo S, Inghilesi AL, Foschi FG, Bernardi M, Marra F, Sacco R, Di Costanzo GG. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. J Cancer Res Clin Oncol 2018;144:403-14. [PMID: 29249005 DOI: 10.1007/s00432-017-2556-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
13 Guo B, Xu X, Shao M, Yang X, He G, Qi K, Gu J, Wang L. UDP-glucose 6-dehydrogenase lessens sorafenib sensitivity via modulating unfolded protein response. Biochem Biophys Res Commun 2022;613:207-13. [PMID: 35617808 DOI: 10.1016/j.bbrc.2022.05.048] [Reference Citation Analysis]
14 Gadaleta-Caldarola G, Infusino S, Divella R, Ferraro E, Mazzocca A, De Rose F, Filippelli G, Abbate I, Brandi M. Sorafenib: 10 years after the first pivotal trial. Future Oncol 2015;11:1863-80. [PMID: 26161924 DOI: 10.2217/fon.15.85] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
15 Katafuchi E, Takami Y, Wada Y, Tateishi M, Ryu T, Mikagi K, Saitsu H. Long-Term Maintenance of Complete Response after Sorafenib Treatment for Multiple Lung Metastases from Hepatocellular Carcinoma. Case Rep Gastroenterol. 2015;9:285-290. [PMID: 26351418 DOI: 10.1159/000438746] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
16 Palmer DH, Johnson PJ. Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma. Cancer Metastasis Rev 2015;34:497-509. [DOI: 10.1007/s10555-015-9580-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
17 Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kitade M, Aihara Y, Douhara A, Kawaratani H, Nishimura N, Fukui H. Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis. J Gastroenterol 2014;49:1421-9. [DOI: 10.1007/s00535-013-0906-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
18 Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol 2015; 7(8): 1041-1053 [PMID: 26052393 DOI: 10.4254/wjh.v7.i8.1041] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
19 Ribeiro de Souza A, Reig M, Bruix J. Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. Expert Opinion on Pharmacotherapy 2016;17:1923-36. [DOI: 10.1080/14656566.2016.1225722] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
20 Iavarone M, Cabibbo G, Biolato M, Della Corte C, Maida M, Barbara M, Basso M, Vavassori S, Craxì A, Grieco A, Cammà C, Colombo M. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology 2015;62:784-91. [PMID: 25645399 DOI: 10.1002/hep.27729] [Cited by in Crossref: 78] [Cited by in F6Publishing: 78] [Article Influence: 11.1] [Reference Citation Analysis]
21 Ochi M, Kamoshida T, Ohkawara A, Ohkawara H, Kakinoki N, Hirai S, Yanaka A. Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 2018; 24(28): 3155-3162 [PMID: 30065561 DOI: 10.3748/wjg.v24.i28.3155] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
22 Xia F, Wu LL, Lau WY, Huan HB, Wen XD, Ma KS, Li XW, Bie P. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. World J Gastroenterol 2016; 22(23): 5384-5392 [PMID: 27340354 DOI: 10.3748/wjg.v22.i23.5384] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
23 Cabibbo G, Celsa C, Enea M, Battaglia S, Rizzo GEM, Grimaudo S, Matranga D, Attanasio M, Bruzzi P, Craxì A, Cammà C. Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. Cancers (Basel) 2020;12:E2132. [PMID: 32752060 DOI: 10.3390/cancers12082132] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
24 Federico A, Orditura M, Cotticelli G, DE Sio I, Romano M, Gravina AG, Dallio M, Fabozzi A, Ciardiello F, Loguercio C. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncol Lett. 2015;9:1628-1632. [PMID: 25789012 DOI: 10.3892/ol.2015.2960] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
25 Witt-Kehati D, Fridkin A, Alaluf MB, Zemel R, Shlomai A. Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus. Transl Oncol 2018;11:511-7. [PMID: 29524828 DOI: 10.1016/j.tranon.2018.02.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
26 Facciorusso A, Licinio R, Carr BI, Di Leo A, Barone M. MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2015;9:993-1003. [PMID: 25915713 DOI: 10.1586/17474124.2015.1040763] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
27 Ferreira CPDC, Ribeiro MA, Szutan LA. Overall survival predictors in hepatocellular carcinoma patients treated with sorafenib. Rev Assoc Med Bras (1992) 2020;66:275-83. [PMID: 32520145 DOI: 10.1590/1806-9282.66.3.275] [Reference Citation Analysis]
28 Wörns MA, Galle PR. Sorafenib for the treatment of hepatocellular carcinoma. Hepat Oncol 2014;1:189-204. [PMID: 30190954 DOI: 10.2217/hep.13.20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
29 Muñoz-Martínez S, Iserte G, Sanduzzi-Zamparelli M, Llarch N, Reig M. Current pharmacological treatment of hepatocellular carcinoma. Curr Opin Pharmacol 2021;60:141-8. [PMID: 34418875 DOI: 10.1016/j.coph.2021.07.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Kaneko S, Ikeda K, Matsuzaki Y, Furuse J, Minami H, Okayama Y, Sunaya T, Ito Y, Inuyama L, Okita K. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. J Gastroenterol 2016;51:1011-21. [PMID: 26931117 DOI: 10.1007/s00535-016-1173-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
31 Zou J, Zhu W, Meng H, Luo P, Zhang J. Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 2019;13:271-9. [PMID: 30791765 DOI: 10.1080/17474124.2019.1570135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Cao Y, Agarwal R, Dituri F, Lupo L, Trerotoli P, Mancarella S, Winter P, Giannelli G. NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC. Cell Death Dis 2017;8:e2634. [PMID: 28230858 DOI: 10.1038/cddis.2017.44] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
33 Loglio A, Iavarone M, Grossi G, Viganò M, Rumi MG, Facchetti F, Lunghi G, Sangiovanni A, Colombo M, Lampertico P. Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. Aliment Pharmacol Ther 2018;48:431-9. [PMID: 29920698 DOI: 10.1111/apt.14848] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
34 Wang Z, Wang E, Bai W, Xia D, Ding R, Li J, Wang Q, Liu L, Sun J, Mu W, Zhao H, Pan X, Shao G, Zhu X, Yin G, Shi H, Wu J, Lin Z, Yang S, Liu J, Wang W, Zhu X, Lv Y, Li J, Chen H, Wang W, Li K, Yuan X, Yu T, Yuan J, Li X, Niu J, Yin Z, Xia J, Fan D, Han G. Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study. Liver Cancer 2020;9:308-25. [PMID: 32647633 DOI: 10.1159/000505692] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Agarwal R, Cao Y, Hoffmeier K, Krezdorn N, Jost L, Meisel AR, Jüngling R, Dituri F, Mancarella S, Rotter B, Winter P, Giannelli G. Precision medicine for hepatocelluar carcinoma using molecular pattern diagnostics: results from a preclinical pilot study. Cell Death Dis 2017;8:e2867. [PMID: 28594404 DOI: 10.1038/cddis.2017.229] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
36 Ouyang G, Pan G, Xu H, Wu Y, Liu Z, Lu W, Yi B, Chen X. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2020;54:675-81. [PMID: 32569032 DOI: 10.1097/MCG.0000000000001384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Carballo-Folgoso L, Álvarez-Velasco R, Lorca R, Castaño-García A, Cuevas J, González-Diéguez ML, Martín M, Álvarez-Navascués C, Cadahía V, Morís C, Rodríguez M, Varela M. Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study. Liver Int 2021;41:2200-11. [PMID: 33966333 DOI: 10.1111/liv.14941] [Reference Citation Analysis]
38 Daniele B, Croitoru A, Papandreou C, Bronowicki J, Mathurin P, Serejo F, Stål P, Turnes J, Ratziu V, Bodoky G. Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. Future Oncology 2015;11:2553-62. [DOI: 10.2217/fon.15.163] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
39 Cabibbo G, Tremosini S, Galati G, Mazza G, Gadaleta-Caldarola G, Lombardi G, Antonucci M, Sacco R. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. Expert Rev Anticancer Ther. 2014;14:831-845. [PMID: 24850249 DOI: 10.1586/14737140.2014.920694] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
40 Colombo M, Raoul J, Lencioni R, Galle PR, Zucman-rossi J, Bañares R, Seehofer D, Neuhaus P, Johnson P. Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. European Journal of Gastroenterology & Hepatology 2013;25:639-51. [DOI: 10.1097/meg.0b013e32835e33bb] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
41 Chao TI, Tai WT, Hung MH, Tsai MH, Chen MH, Chang MJ, Shiau CW, Chen KF. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. Cancer Lett. 2016;371:205-213. [PMID: 26679051 DOI: 10.1016/j.canlet.2015.11.039] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
42 Cabibbo G, Celsa C, Cammà C, Craxì A. Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer? Liver Int 2018;38:2108-16. [PMID: 29935096 DOI: 10.1111/liv.13918] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
43 Iezzi R, Pompili M, Rinninella E, Annicchiarico E, Garcovich M, Cerrito L, Ponziani F, De Gaetano A, Siciliano M, Basso M, Zocco MA, Rapaccini G, Posa A, Carchesio F, Biolato M, Giuliante F, Gasbarrini A, Manfredi R; HepatoCatt Study Group. TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. Eur Radiol. 2019;29:1285-1292. [PMID: 30171360 DOI: 10.1007/s00330-018-5692-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
44 Daniele G, Costa N, Lorusso V, Costa-Maia J, Pache I, Pirisi M. Methodological assessment of HCC literature. Ann Oncol 2013;24 Suppl 2:ii6-14. [PMID: 23715943 DOI: 10.1093/annonc/mdt052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
45 Reig M, Torres F, Rodriguez-lope C, Forner A, Llarch N, Rimola J, Darnell A, Ríos J, Ayuso C, Bruix J. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. Journal of Hepatology 2014;61:318-24. [DOI: 10.1016/j.jhep.2014.03.030] [Cited by in Crossref: 146] [Cited by in F6Publishing: 142] [Article Influence: 18.3] [Reference Citation Analysis]
46 Cabibbo G, Aghemo A, Lai Q, Masarone M, Montagnese S, Ponziani FR. Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.01.122] [Reference Citation Analysis]
47 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. J Hepatol 2017;67:173-83. [PMID: 28323121 DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 90] [Cited by in F6Publishing: 100] [Article Influence: 18.0] [Reference Citation Analysis]
48 Mancuso A. Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol 2013; 5(6): 302-310 [PMID: 23805354 DOI: 10.4254/wjh.v5.i6.302] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
49 Bruix J, Takayama T, Mazzaferro V, Chau G-Y, Yang J, Kudo M, Cai J, Poon RT, Han K-H, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Le Berre Marie-Aude, Meinhardt G, Llovet JM, investigators S. Articles Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16: :1344-1354. [PMID: 26361969 DOI: 10.1016/s1470-2045(15)00198-9] [Cited by in Crossref: 436] [Cited by in F6Publishing: 222] [Article Influence: 62.3] [Reference Citation Analysis]
50 Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi FG, De Matteis S, Ercolani G, Valgiusti M, Frassineti GL, Scartozzi M, Casadei Gardini A. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? World J Gastroenterol 2018; 24(36): 4152-4163 [PMID: 30271080 DOI: 10.3748/wjg.v24.i36.4152] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 63] [Article Influence: 18.0] [Reference Citation Analysis]
51 Ferrarese A, Sciarrone SS, Pellone M, Shalaby S, Battistella S, Zanetto A, Germani G, Russo FP, Senzolo M, Burra P, Gambato M. Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. Minerva Gastroenterol 2021;67. [DOI: 10.23736/s2724-5985.20.02775-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Nenu I, Breaban I, Pascalau S, Bora CN, Stefanescu H. The future is now: beyond first line systemic therapy in hepatocellular carcinoma. Transl Cancer Res 2019;8:S261-74. [PMID: 35117106 DOI: 10.21037/tcr.2018.11.23] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Zhang P, Yang Y, Wen F, He X, Tang R, Du Z, Zhou J, Zhang J, Li Q. Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2015;27:853-859. [PMID: 25919775 DOI: 10.1097/meg.0000000000000373] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
54 Montella L, Addeo R, Cennamo G, Vincenzi B, Palmieri R, Sperlongano P, Sperlongano R, Iodice P, Russo P, Del Prete S. Sorafenib in elderly patients with advanced hepatocellular carcinoma: A case series. Oncology. 2013;84:265-272. [PMID: 23428832 DOI: 10.1159/000345558] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
55 Gao B, Wang H, Lafdil F, Feng D. STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver. J Hepatol. 2012;57:430-441. [PMID: 22504331 DOI: 10.1016/j.jhep.2012.01.029] [Cited by in Crossref: 90] [Cited by in F6Publishing: 95] [Article Influence: 9.0] [Reference Citation Analysis]
56 Iavarone M, Primignani M, Vavassori S, Sangiovanni A, La Mura V, Romeo R, Colombo M. Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. United European Gastroenterol J 2016;4:363-70. [PMID: 27403302 DOI: 10.1177/2050640615615041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
57 Mancuso A, Mazzola A, Cabibbo G, Perricone G, Enea M, Galvano A, Zavaglia C, Belli L, Cammà C. Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis. Dig Liver Dis 2015;47:324-30. [PMID: 25641331 DOI: 10.1016/j.dld.2015.01.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
58 Kanai F, Obi S, Fujiyama S, Shiina S, Tamai H, Mochizuki H, Koike Y, Imamura J, Yamaguchi T, Saida I, Yokosuka O, Omata M. An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma. Hepatol Int 2014;8:94-103. [PMID: 26202410 DOI: 10.1007/s12072-013-9459-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
59 Katayama K, Kiyota R, Imai T, Abe Y, Nawa T, Wada H, Ohkawa K. Factors Affecting Therapeutic Effects in 17 Patients with Advanced Hepatocellular Carcinoma Who Were Treated with Sorafenib for More than 12 Months. Case Rep Oncol 2018;11:711-20. [PMID: 30483103 DOI: 10.1159/000493853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
60 Zhang XP, Chai ZT, Gao YZ, Chen ZH, Wang K, Shi J, Guo WX, Zhou TF, Ding J, Cong WM, Xie D, Lau WY, Cheng SQ. Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis. HPB (Oxford) 2019;21:1687-96. [PMID: 31153833 DOI: 10.1016/j.hpb.2019.04.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
61 Zhou K, Fountzilas C. Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E861. [PMID: 31234316 DOI: 10.3390/cancers11060861] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
62 Bitzer M, Horger M, Giannini EG, Ganten TM, Wörns MA, Siveke JT, Dollinger MM, Gerken G, Scheulen ME, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek NP, Holzapfel J, Herz T, Ammendola AS, Pegoraro S, Hauns B, Mais A, Lauer UM, Henning SW, Hentsch B. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. J Hepatol 2016;65:280-8. [PMID: 26952006 DOI: 10.1016/j.jhep.2016.02.043] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 11.3] [Reference Citation Analysis]
63 DA Fonseca LG, Barroso-Sousa R, Bento AD, Blanco BP, Valente GL, Pfiffer TE, Hoff PM, Sabbaga J. Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. Mol Clin Oncol 2015;3:793-6. [PMID: 26171182 DOI: 10.3892/mco.2015.536] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
64 Sacco R, Antonucci M, Bargellini I, Marceglia S, Mismas V, Cabibbo G. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice? Future Oncology 2015;11:2371-3. [DOI: 10.2217/fon.15.173] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
65 Borzio M, Fornari F, De Sio I, Andriulli A, Terracciano F, Parisi G, Francica G, Salvagnini M, Marignani M, Salmi A, Farinati F, Carella A, Pedicino C, Dionigi E, Fanigliulo L, Cazzaniga M, Ginanni B, Sacco R; EpaHCC Group. Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study. Future Oncol 2013;9:283-94. [PMID: 23414477 DOI: 10.2217/fon.12.183] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
66 An L, Liao H, Yuan K. Efficacy and Safety of Second-line Treatments in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: A Meta-analysis. J Clin Transl Hepatol 2021;9:868-77. [PMID: 34966650 DOI: 10.14218/JCTH.2021.00054] [Reference Citation Analysis]
67 Ehling J, Tacke F. Role of chemokine pathways in hepatobiliary cancer. Cancer Lett. 2015; Jun 26. [Epub ahead of print]. [PMID: 26123664 DOI: 10.1016/j.canlet.2015.06.017] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
68 Trovato FM, Tognarelli JM, Crossey MM, Catalano D, Taylor-Robinson SD, Trovato GM. Challenges of liver cancer: Future emerging tools in imaging and urinary biomarkers. World J Hepatol 2015; 7(26): 2664-2675 [PMID: 26609343 DOI: 10.4254/wjh.v7.i26.2664] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
69 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015;7:738-52. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Reference Citation Analysis]
70 Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev. 2018;68:16-24. [PMID: 29783126 DOI: 10.1016/j.ctrv.2018.05.006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 17.0] [Reference Citation Analysis]
71 Rimola J, Díaz-González Á, Darnell A, Varela M, Pons F, Hernandez-Guerra M, Delgado M, Castroagudin J, Matilla A, Sangro B, Rodriguez de Lope C, Sala M, Gonzalez C, Huertas C, Minguez B, Ayuso C, Bruix J, Reig M. Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. Hepatology 2018;67:612-22. [PMID: 28898447 DOI: 10.1002/hep.29515] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
72 Sohn W, Paik YH, Cho JY, Lim HY, Ahn JM, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. J Hepatol. 2015;62:1112-1121. [PMID: 25514557 DOI: 10.1016/j.jhep.2014.12.009] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
73 Ye SL, Chen X, Yang J, Bie P, Zhang S, Liu F, Liu L, Zhou J, Dou K, Hao C, Shao G, Xia Q, Chen Y, Yang J, Deng X, Liu Y, Yuan Y, Fu Z, Nakajima K, Yip CS, Lu Z. Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. Oncotarget 2016;7:6639-48. [PMID: 26735891 DOI: 10.18632/oncotarget.6781] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
74 Lee IC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lin HC, Lee FY, Huang YH. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Medicine (Baltimore). 2015;94:e688. [PMID: 25860213 DOI: 10.1097/md.0000000000000688] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
75 Fabregat I, Moreno-càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G, ten Dijke P; the IT-LIVER Consortium. TGF-β signalling and liver disease. FEBS J 2016;283:2219-32. [DOI: 10.1111/febs.13665] [Cited by in Crossref: 247] [Cited by in F6Publishing: 243] [Article Influence: 41.2] [Reference Citation Analysis]
76 Sasdelli AS, Brodosi L, Marchesini G. NAFLD-Associated Hepatocellular Carcinoma: a Threat to Patients with Metabolic Disorders. Curr Hepatology Rep 2016;15:103-12. [DOI: 10.1007/s11901-016-0297-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
77 Brunetti O, Gnoni A, Licchetta A, Longo V, Calabrese A, Argentiero A, Delcuratolo S, Solimando AG, Casadei-Gardini A, Silvestris N. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib. Medicina (Kaunas) 2019;55:E707. [PMID: 31640191 DOI: 10.3390/medicina55100707] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
78 Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1:e000042. [PMID: 27843598 DOI: 10.1136/esmoopen-2016-000042] [Cited by in Crossref: 108] [Cited by in F6Publishing: 94] [Article Influence: 18.0] [Reference Citation Analysis]
79 Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N, Milicevic M. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol 2015; 7(20): 2274-2291 [PMID: 26380652 DOI: 10.4254/wjh.v7.i20.2274] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
80 McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, Tariq N, Valle JW, Hubner RA, Knox JJ, Amir E. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis. Eur J Cancer 2018;105:1-9. [PMID: 30384012 DOI: 10.1016/j.ejca.2018.09.031] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
81 Sánchez AIP, Roces LV, García IZ, López EL, Hernandez MAC, Parejo MIB, Peña-Díaz J. Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncol Lett 2018;15:8863-70. [PMID: 29805623 DOI: 10.3892/ol.2018.8400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
82 Shingina A, Hashim AM, Haque M, Suen M, Yoshida EM, Gill S, Donnellan F, Weiss AA. In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival. Can J Gastroenterol 2013;27:393-6. [PMID: 23862169 DOI: 10.1155/2013/170546] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
83 Sacco R, Bargellini I, Ginanni B, Bertini M, Faggioni L, Federici G, Romano A, Bertoni M, Metrangolo S, Altomare E. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice? Expert Rev Anticancer Ther. 2012;12:869-875. [PMID: 22845401 DOI: 10.1586/era.12.58] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
84 King J, Palmer DH, Johnson P, Ross P, Hubner RA, Sumpter K, Darby S, Braconi C, Iwuji C, Swinson D, Collins P, Patel K, Nobes J, Muazzam I, Blesing C, Kirkwood A, Nash S, Meyer T. Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit. Clin Oncol (R Coll Radiol). 2017;29:256-262. [PMID: 27964898 DOI: 10.1016/j.clon.2016.11.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
85 Rimassa L, Pressiani T, Merle P. Systemic Treatment Options in Hepatocellular Carcinoma. Liver Cancer. 2019;8:427-446. [PMID: 31799201 DOI: 10.1159/000499765] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
86 Ho JC, Hsieh ML, Chuang PH, Hsieh VC. Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Value Health Reg Issues 2018;15:120-6. [PMID: 29704658 DOI: 10.1016/j.vhri.2017.12.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
87 Elsadek B, Mansour A, Saleem T, Warnecke A, Kratz F. The antitumor activity of a lactosaminated albumin conjugate of doxorubicin in a chemically induced hepatocellular carcinoma rat model compared to sorafenib. Digestive and Liver Disease 2017;49:213-22. [DOI: 10.1016/j.dld.2016.10.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
88 Cabibbo G, Maida M, Genco C, Parisi P, Peralta M, Antonucci M, Brancatelli G, Cammà C, Craxì A, Di Marco V. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J Hepatol 2012; 4(9): 256-261 [PMID: 23060970 DOI: 10.4254/wjh.v4.i9.256] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 4.7] [Reference Citation Analysis]
89 de la Torre MA, Buades-Mateu J, de la Rosa PA, Lué A, Bustamante FJ, Serrano MT, Testillano M, Lorente S, Arenas JI, Gil C, Iñarrairaegui M, Sangro B. A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. Liver Int 2016;36:1206-12. [PMID: 26910784 DOI: 10.1111/liv.13098] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
90 Pressiani T, Boni C, Rimassa L, Labianca R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciarini C. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol. 2013;24:406-411. [PMID: 23041587 DOI: 10.1093/annonc/mds343] [Cited by in Crossref: 74] [Cited by in F6Publishing: 81] [Article Influence: 7.4] [Reference Citation Analysis]
91 Nawa T, Katayama K, Kiyota R, Imai T, Abe Y, Hasegawa N, Takada R, Fukutake N, Ikezawa K, Sakakibara M, Fujita M, Ohkawa K. Development of a thrombus in the superior mesenteric artery associated with sequential therapy with tyrosine kinase inhibitors for hepatocellular carcinoma. Clin J Gastroenterol 2020;13:247-51. [PMID: 31317371 DOI: 10.1007/s12328-019-01021-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Shimose S, Hiraoka A, Nakano M, Iwamoto H, Tanaka M, Tanaka T, Noguchi K, Aino H, Ogata K, Kajiwara M, Itano S, Yokokura Y, Yamaguchi T, Kawano H, Matsukuma N, Suga H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Kawaguchi T, Koga H, Torimura T. First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study. Cancer Med 2021. [PMID: 34693661 DOI: 10.1002/cam4.4367] [Reference Citation Analysis]
93 Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2014;68:609-17. [PMID: 24283303 DOI: 10.1111/ijcp.12352] [Cited by in Crossref: 154] [Cited by in F6Publishing: 140] [Article Influence: 17.1] [Reference Citation Analysis]
94 Kalyan A, Nimeiri H, Kulik L. Systemic therapy of hepatocellular carcinoma: current and promising. Clin Liver Dis 2015;19:421-32. [PMID: 25921671 DOI: 10.1016/j.cld.2015.01.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
95 Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Benvegnù L, Caturelli E, Zoli M, Borzio F, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Prognosis of untreated hepatocellular carcinoma. Hepatology 2015;61:184-90. [PMID: 25234419 DOI: 10.1002/hep.27443] [Cited by in Crossref: 110] [Cited by in F6Publishing: 110] [Article Influence: 15.7] [Reference Citation Analysis]
96 Tovoli F, Lorenzo S, Barbera MA, Garajova I, Frega G, Palloni A, Pantaleo MA, Biasco G, Brandi G. Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial. Future Oncol 2017;13:1893-905. [PMID: 28693355 DOI: 10.2217/fon-2017-0166] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
97 Huang K, Lee P, Chao Y, Su C, Lee I, Lan K, Chu C, Hung Y, Chen S, Hou M, Huang Y. Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. Ther Adv Med Oncol 2022;14:175883592210994. [DOI: 10.1177/17588359221099401] [Reference Citation Analysis]
98 Reis D, Moura M, Freitas LC, Carvalhana S, Nogueira PJ, Gaio R, Marinho RT, Cortez-Pinto H. Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2020. [PMID: 33177383 DOI: 10.1097/MEG.0000000000001974] [Reference Citation Analysis]
99 Chaoul N, Mancarella S, Lupo L, Giannelli G, Dituri F. Impaired Anti-Tumor T cell Response in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E627. [PMID: 32182707 DOI: 10.3390/cancers12030627] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
100 Ogasawara S, Chiba T, Ooka Y, Suzuki E, Inoue M, Wakamatsu T, Tawada A, Yokosuka O. Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. PLoS One 2016;11:e0161303. [PMID: 27537374 DOI: 10.1371/journal.pone.0161303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
101 Biolato M, Galasso T, Marrone G, Miele L, Grieco A. Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation. Cancers (Basel) 2021;13:6337. [PMID: 34944957 DOI: 10.3390/cancers13246337] [Reference Citation Analysis]
102 Rimassa L, Personeni N, Czauderna C, Foerster F, Galle P. Systemic treatment of HCC in special populations. J Hepatol 2021;74:931-43. [PMID: 33248171 DOI: 10.1016/j.jhep.2020.11.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
103 Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Satani M, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group Of Japan. Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. Oncotarget 2016;7:64400-9. [PMID: 27462865 DOI: 10.18632/oncotarget.10794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
104 Reig M, Gazzola A, Di Donato R, Bruix J. Systemic treatment. Best Practice & Research Clinical Gastroenterology 2014;28:921-35. [DOI: 10.1016/j.bpg.2014.08.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
105 Tovoli F, Ielasi L, Casadei-Gardini A, Granito A, Foschi FG, Rovesti G, Negrini G, Orsi G, Renzulli M, Piscaglia F. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. J Hepatol 2019;71:1175-83. [PMID: 31449860 DOI: 10.1016/j.jhep.2019.08.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
106 Wang Q, Xia D, Bai W, Wang E, Sun J, Huang M, Mu W, Yin G, Li H, Zhao H, Li J, Zhang C, Zhu X, Wu J, Gong W, Li Z, Lin Z, Pan X, Shi H, Shao G, Liu J, Yang S, Zheng Y, Xu J, Song J, Wang W, Wang Z, Zhang Y, Ding R, Zhang H, Yu H, Zheng L, Gu W, You N, Wang G, Zhang S, Feng L, Liu L, Zhang P, Li X, Chen J, Xu T, Zhou W, Zeng H, Huang W, Jiang W, Zhang W, Shao W, Li L, Niu J, Yuan J, Lv Y, Li K, Yin Z, Xia J, Fan D, Han G;  China HCC-TACE Study Group. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol. 2019;70:893-903. [PMID: 30660709 DOI: 10.1016/j.jhep.2019.01.013] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 16.7] [Reference Citation Analysis]
107 Colombo GL, Cammà C, Attili AF, Ganga R, Gaeta GB, Brancaccio G, Franzini JM, Volpe M, Turchetti G. Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers. Ther Clin Risk Manag 2015;11:1603-12. [PMID: 26527877 DOI: 10.2147/TCRM.S88208] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
108 Eso Y, Takai A, Takahashi K, Ueda Y, Taura K, Marusawa H, Seno H. Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E405. [PMID: 30909405 DOI: 10.3390/cancers11030405] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
109 Doyle A, Marsh P, Gill R, Rodov M, Mohsen W, Varma P, Hong T, Strasser SI, Bell S, Ryan M, Nicoll A, Lubel J, Gow PJ, Fink MA, Roberts S, Kemp W, Kronborg I, Arachchi N, Knight V, Dev A. Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study. Scandinavian Journal of Gastroenterology 2016;51:979-85. [DOI: 10.3109/00365521.2016.1166518] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
110 Cabibbo G, Cucchetti A, Cammà C, Casadei-Gardini A, Celsa C, Emanuele Maria Rizzo G, Johnson P, Ercolani G. Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials. Future Oncol 2019;15:3411-22. [PMID: 31588789 DOI: 10.2217/fon-2019-0287] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
111 Rognoni C, Ciani O, Sommariva S, Bargellini I, Bhoori S, Cioni R, Facciorusso A, Golfieri R, Gramenzi A, Mazzaferro V, Mosconi C, Ponziani F, Sacco R, Trevisani F, Tarricone R. Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. BMC Cancer. 2018;18:715. [PMID: 29976149 DOI: 10.1186/s12885-018-4636-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
112 Rognoni C, Ciani O, Sommariva S, Facciorusso A, Tarricone R, Bhoori S, Mazzaferro V. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget. 2016;7:72343-72355. [PMID: 27579537 DOI: 10.18632/oncotarget.11644] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
113 Zhao Y, Duran R, Chapiro J, Sohn JH, Sahu S, Fleckenstein F, Smolka S, Pawlik TM, Schernthaner R, Zhao L, Lee H, He S, Lin M, Geschwind JF. Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma. J Gastrointest Surg 2016;20:2002-9. [PMID: 27714643 DOI: 10.1007/s11605-016-3285-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
114 Ziogas IA, Tsoulfas G. Evolving role of Sorafenib in the management of hepatocellular carcinoma. World J Clin Oncol 2017; 8(3): 203-213 [PMID: 28638790 DOI: 10.5306/wjco.v8.i3.203] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
115 Woo HY, Heo J. Sorafenib in liver cancer. Expert Opin Pharmacother. 2012;13:1059-1067. [PMID: 22519770 DOI: 10.1517/14656566.2012.679930] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
116 Nakano M, Niizeki T, Nagamatsu H, Tanaka M, Kuromatsu R, Satani M, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study. Mol Clin Oncol 2017;7:1013-20. [PMID: 29285366 DOI: 10.3892/mco.2017.1442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
117 Teuwen LA, Van den Mooter T, Dirix L. Management of pulmonary toxicity associated with targeted anticancer therapies. Expert Opin Drug Metab Toxicol 2015;11:1695-707. [PMID: 26293379 DOI: 10.1517/17425255.2015.1080687] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
118 Carr BI, D’Alessandro R, Refolo MG, Iacovazzi PA, Lippolis C, Messa C, Cavallini A, Correale M, Di Carlo A. Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro. J Cell Physiol. 2013;228:1344-1350. [PMID: 23169148 DOI: 10.1002/jcp.24291] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
119 Kuo YH, Wang JH, Hung CH, Rau KM, Wu IP, Chen CH, Kee KM, Hu TH, Lu SN. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. J Gastroenterol Hepatol. 2017;32:1975-1981. [PMID: 28295594 DOI: 10.1111/jgh.13783] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 7.3] [Reference Citation Analysis]
120 Alqahtani SA, Colombo MG. Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma . World J Gastrointest Oncol 2021; 13(12): 2038-2049 [DOI: 10.4251/wjgo.v13.i12.2038] [Reference Citation Analysis]
121 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015; 7(5): 738-752 [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 5.1] [Reference Citation Analysis]
122 Marasco G, Colecchia A, Bacchi Reggiani ML, Celsa C, Farinati F, Giannini EG, Benevento F, Rapaccini GL, Caturelli E, Di Marco M, Biasini E, Marra F, Morisco F, Foschi FG, Zoli M, Gasbarrini A, Baroni GS, Masotto A, Sacco R, Raimondo G, Azzaroli F, Mega A, Vidili G, Brunetto MR, Nardone G, Dajti E, Ravaioli F, Avanzato F, Festi D, Trevisani F; Italian Liver Cancer (ITA.LI.CA.) group. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study. Dig Liver Dis 2021;53:1011-9. [PMID: 33353858 DOI: 10.1016/j.dld.2020.12.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
123 Shiba S, Okusaka T, Ikeda M, Saito H, Ichida T. Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib. Hepatol Res. 2014;44:1268-1276. [PMID: 24405694 DOI: 10.1111/hepr.12297] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
124 Labeur TA, Ten Cate DWG, Bart Takkenberg R, Azahaf H, van Oijen MGH, van Delden OM, de Man RA, van Vugt JLA, IJzermans JNM, Eskens FALM, Klümpen HJ. Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma. Acta Oncol 2018;57:1467-74. [PMID: 29943624 DOI: 10.1080/0284186X.2018.1479070] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
125 Tantawy HI, Mohamed FF. Diagnostic value of apparent diffusion coefficient (ADC) in evaluating hepatocellular carcinomas post trans-catheter arterial chemoembolization and radiofrequency ablation. The Egyptian Journal of Radiology and Nuclear Medicine 2016;47:699-706. [DOI: 10.1016/j.ejrnm.2016.05.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
126 Scartozzi M, Faloppi L, Svegliati Baroni G, Loretelli C, Piscaglia F, Iavarone M, Toniutto P, Fava G, De Minicis S, Mandolesi A, Bianconi M, Giampieri R, Granito A, Facchetti F, Bitetto D, Marinelli S, Venerandi L, Vavassori S, Gemini S, D'Errico A, Colombo M, Bolondi L, Bearzi I, Benedetti A, Cascinu S. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer. 2014;135:1247-1256. [PMID: 24510746 DOI: 10.1002/ijc.28772] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 9.1] [Reference Citation Analysis]
127 Diaz-Beveridge R, Bruixola G, Lorente D, Caballero J, Rodrigo E, Segura Á, Akhoundova D, Giménez A, Aparicio J. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib. Clin Transl Oncol 2018;20:322-9. [PMID: 28801777 DOI: 10.1007/s12094-017-1720-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
128 Surveillance group. ; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117:381-403. [PMID: 29074347 DOI: 10.1016/j.jfma.2017.09.007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
129 Zheng J, Shao G, Luo J. Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib. Clin Transl Oncol. 2014;16:1012-1017. [PMID: 24894839 DOI: 10.1007/s12094-014-1189-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
130 Cerrito L, Santopaolo F, Monti F, Pompili M, Gasbarrini A, Ponziani FR. Advances in pharmacotherapeutics for hepatocellular carcinoma. Expert Opin Pharmacother 2021;22:1343-54. [PMID: 33637024 DOI: 10.1080/14656566.2021.1892074] [Reference Citation Analysis]
131 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
132 Granito A, Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. The Lancet Oncology 2017;18:e101-12. [DOI: 10.1016/s1470-2045(16)30569-1] [Cited by in Crossref: 62] [Cited by in F6Publishing: 35] [Article Influence: 12.4] [Reference Citation Analysis]
133 Morimoto M, Numata K, Kondo M, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Okuwaki Y, Okuse C, Matsunaga K, Suzuki M, Morita S, Taguri M, Tanaka K. Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysis. Hepatol Res. 2015;45:279-287. [PMID: 24802232 DOI: 10.1111/hepr.12354] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
134 Ogasawara S, Kanai F, Ooka Y, Motoyama T, Suzuki E, Tawada A, Chiba T, Yokosuka O. Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma. Hepatol Int 2013;7:703-13. [DOI: 10.1007/s12072-013-9425-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
135 Scandurra G, Aiello RA, Alì M, Taibi E, Sanò MV, Todaro FM, La Rocca R, Licciardello P, Caruso M. Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience. Future Oncology 2012;8:609-15. [DOI: 10.2217/fon.12.35] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
136 Merchante N, Ibarra S, Revollo B, Rodríguez-Arrondo F, Merino E, Delgado-Fernández M, Montero-Alonso M, Téllez F, Galindo MJ, Rivero-Juárez A, García MA, Mínguez C, Romero-Palacios A, Garcia-Deltoro M, Pineda JA; GEHEP-002 Study Group. Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients. AIDS 2017;31:89-95. [PMID: 27755109 DOI: 10.1097/QAD.0000000000001293] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
137 Turnes J, Díaz R, Hernandez-Guerra M, Gómez M, Castells L, Bustamante J, Espinosa MD, Fernández-Castroagudín J, Serrano T, Rendón P, Andrade R, Salgado M, Arenas J, Vergara M, Sala M, Polo BA, Granizo IM, Gonzálvez ML, Viudez A. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain]. Gastroenterol Hepatol 2015;38:263-73. [PMID: 25583146 DOI: 10.1016/j.gastrohep.2014.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
138 Weintraub JL, Salem R. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science. J Vasc Interv Radiol. 2013;24:1123-1134. [PMID: 23562168 DOI: 10.1016/j.jvir.2013.01.494] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
139 Labeur TA, van Vugt JLA, Ten Cate DWG, Takkenberg RB, IJzermans JNM, Groot Koerkamp B, de Man RA, van Delden OM, Eskens FALM, Klümpen HJ. Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Liver Cancer 2019;8:255-70. [PMID: 31602369 DOI: 10.1159/000493586] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
140 Au JS, Frenette CT. Management of Hepatocellular Carcinoma: Current Status and Future Directions. Gut Liver. 2015;9:437-448. [PMID: 26087860 DOI: 10.5009/gnl15022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
141 Díaz-González Á, Sanduzzi-Zamparelli M, da Fonseca LG, Di Costanzo GG, Alves R, Iavarone M, Leal C, Sacco R, Matilla AM, Hernández-Guerra M, Aballay Soteras G, Wörns MA, Pinter M, Varela M, Ladekarl M, Chagas AL, Mínguez B, Arenas JI, Granito A, Sánchez-Torrijos Y, Rojas Á, Rodríguez de Lope C, Alvares-da-Silva MR, Pascual S, Rimassa L, Lledó JL, Huertas C, Sangro B, Giannini EG, Delgado M, Vergara M, Perelló C, Lue A, Sala M, Gallego A, Coll S, Hernáez T, Piñero F, Pereira G, França A, Marín J, Anders M, Mello V, Lozano M, Nault JC, Menéndez J, García Juárez I, Bruix J, Reig M. International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. Liver Int 2020;40:1467-76. [PMID: 32170821 DOI: 10.1111/liv.14436] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
142 Doycheva I, Thuluvath PJ. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field. J Clin Exp Hepatol. 2019;9:588-596. [PMID: 31695249 DOI: 10.1016/j.jceh.2019.07.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
143 Zhong BY, Ni CF, Chen L, Zhu HD, Teng GJ. Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma. Radiology 2017;284:583-92. [PMID: 28263701 DOI: 10.1148/radiol.2017161975] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
144 Feng J, Lu PZ, Zhu GZ, Hooi SC, Wu Y, Huang XW, Dai HQ, Chen PH, Li ZJ, Su WJ, Han CY, Ye XP, Peng T, Zhou J, Lu GD. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma. Acta Pharmacol Sin 2021;42:160-70. [PMID: 32541921 DOI: 10.1038/s41401-020-0439-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 24.0] [Reference Citation Analysis]
145 Maida M, Iavarone M, Raineri M, Cammà C, Cabibbo G. Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure. World J Hepatol 2015; 7(17): 2053-2057 [PMID: 26301047 DOI: 10.4254/wjh.v7.i17.2053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
146 Lee PC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lee MH, Hou MC, Lee FY, Lin HC, Huang YH. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. Liver Int. 2018;38:321-330. [PMID: 28736952 DOI: 10.1111/liv.13527] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
147 Giannini EG, Bucci L, Garuti F, Brunacci M, Lenzi B, Valente M, Caturelli E, Cabibbo G, Piscaglia F, Virdone R, Felder M, Ciccarese F, Foschi FG, Sacco R, Svegliati Baroni G, Farinati F, Rapaccini GL, Olivani A, Gasbarrini A, Di Marco M, Morisco F, Zoli M, Masotto A, Borzio F, Benvegnù L, Marra F, Colecchia A, Nardone G, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology 2018;67:1784-96. [PMID: 29159910 DOI: 10.1002/hep.29668] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 15.8] [Reference Citation Analysis]
148 Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53. [PMID: 27785449 DOI: 10.2147/jhc.s61146] [Cited by in Crossref: 418] [Cited by in F6Publishing: 256] [Article Influence: 69.7] [Reference Citation Analysis]
149 Peng S, Zhao Y, Xu F, Jia C, Xu Y, Dai C. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma. PLoS One. 2014;9:e112530. [PMID: 25460347 DOI: 10.1371/journal.pone.0112530] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
150 Ponziani FR, Bhoori S, Germini A, Bongini M, Flores M, Sposito C, Facciorusso A, Gasbarrini A, Mazzaferro V. Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. Liver Int 2016;36:1033-42. [PMID: 26709844 DOI: 10.1111/liv.13052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
151 Abou-Alfa GK. Sorafenib use in hepatocellular carcinoma: more questions than answers. Hepatology 2014;60:15-8. [PMID: 24493250 DOI: 10.1002/hep.27044] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
152 Mossanen JC, Tacke F. Role of lymphocytes in liver cancer. Oncoimmunology 2013;2:e26468. [PMID: 24498546 DOI: 10.4161/onci.26468] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
153 Dufour J, Bargellini I, De Maria N, De Simone P, Goulis I, Marinho R. Intermediate hepatocellular carcinoma: current treatments and future perspectives. Annals of Oncology 2013;24:24-9. [DOI: 10.1093/annonc/mdt054] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
154 Cabrera R, Ararat M, Xu Y, Brusko T, Wasserfall C, Atkinson MA, Chang LJ, Liu C, Nelson DR. Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma. Cancer Immunol Immunother 2013;62:737-46. [PMID: 23223899 DOI: 10.1007/s00262-012-1380-8] [Cited by in Crossref: 70] [Cited by in F6Publishing: 76] [Article Influence: 7.0] [Reference Citation Analysis]
155 Moriguchi M, Aramaki T, Nishiofuku H, Sato R, Asakura K, Yamaguchi K, Tanaka T, Endo M, Itoh Y. Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis. Liver Cancer 2017;6:275-86. [PMID: 29234631 DOI: 10.1159/000473887] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
156 Hsu CY, Liu PH, Hsia CY, Lee YH, Al Juboori A, Lee RC, Lin HC, Huo TI. Nomogram of the Barcelona Clinic Liver Cancer system for individual prognostic prediction in hepatocellular carcinoma. Liver Int. 2016;36:1498-1506. [PMID: 26972815 DOI: 10.1111/liv.13114] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
157 Schmidt N, Neumann-Haefelin C, Thimme R. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy. Dig Dis. 2012;30:483-491. [PMID: 23108304 DOI: 10.1159/000341697] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
158 Hsu CH, Shen YC, Shao YY, Hsu C, Cheng AL. Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. J Hepatocell Carcinoma 2014;1:85-99. [PMID: 27508178 DOI: 10.2147/JHC.S45040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
159 Sacco R, Faggioni L, Bargellini I, Romano A, Bertini M, Ginanni B, Battaglia V, Bertoni M, Bozzi E, Federici G, Metrangolo S, Parisi G, Neri E, Sodini E, Tumino E, Bresci G, Bartolozzi C. Treatment Response After Unusual Low Dose Sorafenib: Diagnosis with Perfusion CT and Follow-up in a Patient with Recurrent Hepatocellular Carcinoma. J Gastrointest Canc 2012;43:234-8. [DOI: 10.1007/s12029-012-9403-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
160 Edeline J, Crouzet L, Le Sourd S, Larible C, Brunot A, Le Roy F, Cattenoz C, Latournerie M, Gédouin D, Guillygomarc'h A, Boucher E. Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. Cancer Chemother Pharmacol 2015;75:215-9. [PMID: 25477009 DOI: 10.1007/s00280-014-2645-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
161 Li J, Shi L, Zhang X, Sun B, Yang Y, Ge N, Liu H, Yang X, Chen L, Qian H. pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncotarget. 2016;7:2646-2659. [PMID: 26544731 DOI: 10.18632/oncotarget.6104] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
162 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
163 Sugimoto K, Moriyasu F, Saito K, Rognin N, Kamiyama N, Furuichi Y, Imai Y. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US. Liver Int. 2013;33:605-615. [PMID: 23305331 DOI: 10.1111/liv.12098] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
164 Huang CC, Chen HY, Chang RH, Liao PA, Lien HH, Hung CS, Yang SS, Hu JT. A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015. Drug Des Devel Ther 2019;13:397-404. [PMID: 30774305 DOI: 10.2147/DDDT.S191334] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
165 Cardoso H, Alves AM, Marques M, Vale AM, Pereira P, Macedo G. Hepatocellular Carcinoma Treatment With Sorafenib: Real-Life Evaluation of Prognostic Factors and a Practical Clue for Patient Management. GE Port J Gastroenterol 2016;23:243-8. [PMID: 28868469 DOI: 10.1016/j.jpge.2016.04.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
166 Agnello F, Salvaggio G, Cabibbo G, Maida M, Lagalla R, Midiri M, Brancatelli G. Imaging appearance of treated hepatocellular carcinoma. World J Hepatol 2013; 5(8): 417-424 [PMID: 24023980 DOI: 10.4254/wjh.v5.i8.417] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
167 Neuzillet C, de Mestier L, Rousseau B, Mir O, Hebbar M, Kocher HM, Ruszniewski P, Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. Pharmacol Ther 2018;181:49-75. [PMID: 28723416 DOI: 10.1016/j.pharmthera.2017.07.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
168 Invernizzi F, Iavarone M, Zavaglia C, Mazza S, Maggi U, Cesarini L, Antonelli B, Airoldi A, Manini MA, Sangiovanni A, Rossi G, Donato MF, Saverio Belli L, Lampertico P. Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation. Transplantation 2020;104:568-74. [DOI: 10.1097/tp.0000000000002955] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
169 Zheng SZ, Liu DJ, Sun P, Yu GS, Xu YT, Gong W, Liu J. Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture. World J Gastroenterol 2014; 20(43): 16275-16281 [PMID: 25473183 DOI: 10.3748/wjg.v20.i43.16275] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
170 Gramenzi A, Golfieri R, Mosconi C, Cappelli A, Granito A, Cucchetti A, Marinelli S, Pettinato C, Erroi V, Fiumana S, Bolondi L, Bernardi M, Trevisani F; BLOG (Bologna Liver Oncology Group). Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. 2015;35:1036-1047. [PMID: 24750853 DOI: 10.1111/liv.12574] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 8.6] [Reference Citation Analysis]
171 Ostwal V, Gupta T, Chopra S, Lewis S, Goel M, Patkar S, Shetty N, Ramaswamy A. Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma. South Asian J Cancer 2017;6:144-6. [PMID: 29404288 DOI: 10.4103/sajc.sajc_44_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
172 Cheung TT, Poon RT, Jenkins CR, Chu FS, Chok KS, Chan AC, Tsang SH, Dai WC, Yau TC, Chan SC. Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas. Liver Int. 2014;34:e136-e143. [PMID: 24451026 DOI: 10.1111/liv.12474] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
173 Moriya K, Namisaki T, Sato S, Douhara A, Furukawa M, Kawaratani H, Kaji K, Kitade M, Shimozato N, Sawada Y, Seki K, Saikawa S, Takaya H, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H. Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. J Gastrointest Oncol. 2018;9:741-749. [PMID: 30151271 DOI: 10.21037/jgo.2018.05.13] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
174 Lee SW, Tung CF, Peng YC, Lien HC, Chang CS. Therapeutic benefits of combined sorafenib for intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population. J Dig Dis 2020;21:462-7. [PMID: 32472590 DOI: 10.1111/1751-2980.12911] [Reference Citation Analysis]
175 Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(34): 7645-7659 [PMID: 27678348 DOI: 10.3748/wjg.v22.i34.7645] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 72] [Article Influence: 12.0] [Reference Citation Analysis]
176 Zheng L, Guo CY, Chen CS, Xiao JC, Hu HT, Cheng HT, Zong DW, Jiang L, Li HL. Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective study. Oncotarget 2017;8:97613-22. [PMID: 29228637 DOI: 10.18632/oncotarget.18811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
177 Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Costanzo FD, Marra F. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 2014; 20(3): 786-794 [PMID: 24574751 DOI: 10.3748/wjg.v20.i3.786] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
178 Chen S, Peng Z, Wei M, Liu W, Dai Z, Wang H, Mei J, Cheong M, Zhang H, Kuang M. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis. BMC Cancer 2018;18:392. [PMID: 29621988 DOI: 10.1186/s12885-018-4308-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
179 Reig M, da Fonseca LG, Faivre S. New trials and results in systemic treatment of HCC. J Hepatol 2018;69:525-33. [PMID: 29653122 DOI: 10.1016/j.jhep.2018.03.028] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 7.3] [Reference Citation Analysis]
180 Zhang EB, Zhang X, Wang K, Zhang F, Chen TW, Ma N, Ni QZ, Wang YK, Zheng QW, Cao HJ, Xia J, Zhu B, Xu S, Ding X, Wang X, Li Z, Cheng S, Xie D, Li JJ. Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis. Oncogene 2021. [PMID: 34247189 DOI: 10.1038/s41388-021-01934-y] [Reference Citation Analysis]
181 Giannelli G, Rani B, Dituri F, Cao Y, Palasciano G. Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. Gut 2014;63:1668-76. [PMID: 25053718 DOI: 10.1136/gutjnl-2014-307323] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 9.0] [Reference Citation Analysis]
182 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Prasad V, Massey PR, Fojo T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol 2014;32:1620-9. [PMID: 24711558 DOI: 10.1200/JCO.2013.53.0204] [Cited by in Crossref: 39] [Cited by in F6Publishing: 13] [Article Influence: 4.9] [Reference Citation Analysis]
184 Bolondi L, Cillo U, Colombo M, Craxì A, Farinati F, Giannini EG, Golfieri R, Levrero M, Pinna AD, Piscaglia F, Raimondo G, Trevisani F, Bruno R, Caraceni P, Ciancio A, Coco B, Fraquelli M, Rendina M, Squadrito G, Toniutto P. Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. Digestive and Liver Disease 2013;45:712-23. [DOI: 10.1016/j.dld.2013.01.012] [Cited by in Crossref: 103] [Cited by in F6Publishing: 113] [Article Influence: 11.4] [Reference Citation Analysis]
185 Santini D, Addeo R, Vincenzi B, Calvieri A, Montella L, Silletta M, Caraglia M, Vespasiani U, Picardi A, Del Prete S. Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. Expert Rev Anticancer Ther. 2012;12:1283-1288. [PMID: 23094801 DOI: 10.1586/era.12.102] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
186 Gong L, Giacomini MM, Giacomini C, Maitland ML, Altman RB, Klein TE. PharmGKB summary: sorafenib pathways. Pharmacogenet Genomics 2017;27:240-6. [PMID: 28362716 DOI: 10.1097/FPC.0000000000000279] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
187 Zhang H, Zhang W, Jiang L, Chen Y. Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res 2022;10:3. [PMID: 35000616 DOI: 10.1186/s40364-021-00350-4] [Reference Citation Analysis]
188 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
189 D’Angelo S, Secondulfo M, De Cristofano R, Sorrentino P. Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit. Future Oncol. 2013;9:485-491. [PMID: 23560372 DOI: 10.2217/fon.12.208] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
190 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3517] [Article Influence: 364.2] [Reference Citation Analysis]
191 Willatt J, Hannawa KK, Ruma JA, Frankel TL, Owen D, Barman PM. Image-guided therapies in the treatment of hepatocellular carcinoma: A multidisciplinary perspective. World J Hepatol 2015; 7(2): 235-244 [PMID: 25729478 DOI: 10.4254/wjh.v7.i2.235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
192 Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol 2015; 7(20): 2245-2263 [PMID: 26380650 DOI: 10.4254/wjh.v7.i20.2245] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
193 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
194 Dong Y, Liu TH, Yau T, Hsu C. Novel systemic therapy for hepatocellular carcinoma. Hepatol Int 2020;14:638-51. [PMID: 32661949 DOI: 10.1007/s12072-020-10073-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
195 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol. 2015;7:738-752. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
196 Li Q, Song T. Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection. Front Oncol 2021;11:633033. [PMID: 34631511 DOI: 10.3389/fonc.2021.633033] [Reference Citation Analysis]
197 Castelli G, Burra P, Giacomin A, Vitale A, Senzolo M, Cillo U, Farinati F. Sorafenib use in the transplant setting. Liver Transpl. 2014;20:1021-1028. [PMID: 24809799 DOI: 10.1002/lt.23911] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
198 Likhitsup A, Parikh ND. Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. Pharmacoeconomics 2020;38:5-24. [PMID: 31573053 DOI: 10.1007/s40273-019-00839-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
199 Piscaglia F, Salvatore V, Venerandi L. Field practice studies on sorafenib: lessons in systemic treatment of hepatocellular carcinoma. Dig Liver Dis. 2013;45:367-368. [PMID: 23562444 DOI: 10.1016/j.dld.2013.02.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
200 Kuo Y, Wu I, Wang J, Hung C, Rau K, Chen C, Kee K, Hu T, Lu S. The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis. Invest New Drugs 2018;36:307-14. [DOI: 10.1007/s10637-017-0468-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
201 Adhoute X, Anty R, Bourlière M. Transarterial chemoembolization (TACE) plus sorafenib: a real winning combination? Ann Transl Med 2020;8:1616. [PMID: 33437815 DOI: 10.21037/atm-20-4268] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
202 Hajiev S, Allara E, Motedayеn Aval L, Arizumi T, Bettinger D, Pirisi M, Rimassa L, Pressiani T, Personeni N, Giordano L, Kudo M, Thimme R, Park JW, Taddei TH, Kaplan DE, Ramaswami R, Pinato DJ, Sharma R. Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. Br J Cancer 2021;124:407-13. [PMID: 33071284 DOI: 10.1038/s41416-020-01116-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
203 Granito A, Marinelli S, Terzi E, Piscaglia F, Renzulli M, Venerandi L, Benevento F, Bolondi L. Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. Dig Liver Dis. 2015;47:518-522. [PMID: 25861840 DOI: 10.1016/j.dld.2015.03.010] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
204 Leoni S, Piscaglia F, Serio I, Terzi E, Pettinari I, Croci L, Marinelli S, Benevento F, Golfieri R, Bolondi L. Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. Dig Liver Dis. 2014;46:549-555. [PMID: 24630947 DOI: 10.1016/j.dld.2014.02.012] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
205 Granito A, Forgione A, Marinelli S, Renzulli M, Ielasi L, Sansone V, Benevento F, Piscaglia F, Tovoli F. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol 2021;14:17562848211016959. [PMID: 34104211 DOI: 10.1177/17562848211016959] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
206 De Lorenzo S, Tovoli F, Barbera MA, Garuti F, Palloni A, Frega G, Garajovà I, Rizzo A, Trevisani F, Brandi G. Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept. Sci Rep 2018;8:9997. [PMID: 29968763 DOI: 10.1038/s41598-018-28337-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
207 Rinninella E, Cerrito L, Spinelli I, Cintoni M, Mele MC, Pompili M, Gasbarrini A. Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. J Clin Transl Hepatol 2017;5:235-48. [PMID: 28936405 DOI: 10.14218/JCTH.2017.00002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
208 Cammarota A, D'Alessio A, Pressiani T, Rimassa L, Personeni N. Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. Drugs Aging 2021;38:579-91. [PMID: 34152589 DOI: 10.1007/s40266-021-00871-5] [Reference Citation Analysis]
209 Bucci L, Garuti F, Camelli V, Lenzi B, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Maida M, Felder M, Morisco F, Gasbarrini A, Gemini S, Foschi FG, Missale G, Masotto A, Affronti A, Bernardi M, Trevisani F; Italian Liver Cancer (ITA. LI.CA) Group; Italian Liver Cancer ITA LI CA Group. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. Aliment Pharmacol Ther. 2016;43:385-399. [PMID: 26662476 DOI: 10.1111/apt.13485] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
210 Moehler M, Maderer A, Schimanski C, Kanzler S, Denzer U, Kolligs FT, Ebert MP, Distelrath A, Geissler M, Trojan J, Schütz M, Berie L, Sauvigny C, Lammert F, Lohse A, Dollinger MM, Lindig U, Duerr EM, Lubomierski N, Zimmermann S, Wachtlin D, Kaiser AK, Schadmand-Fischer S, Galle PR, Woerns M; Working Group of Internal Oncology. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. Eur J Cancer 2014;50:3125-35. [PMID: 25446376 DOI: 10.1016/j.ejca.2014.09.013] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 9.8] [Reference Citation Analysis]
211 Antonelli G, Gigante E, Iavarone M, Begini P, Sangiovanni A, Iannicelli E, Biondetti P, Pellicelli AM, Miglioresi L, Marchetti P, Lampertico P, Marignani M. Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. United European Gastroenterol J 2018;6:1039-48. [PMID: 30228892 DOI: 10.1177/2050640618781188] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
212 Shomura M, Kagawa T, Shiraishi K, Hirose S, Arase Y, Koizumi J, Mine T. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol 2014; 6(9): 670-676 [PMID: 25276283 DOI: 10.4254/wjh.v6.i9.670] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
213 Qin S, Finn RS, Kudo M, Meyer T, Vogel A, Ducreux M, Macarulla TM, Tomasello G, Boisserie F, Hou J, Li X, Song J, Zhu AX. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncol 2019;15:1811-22. [PMID: 30969136 DOI: 10.2217/fon-2019-0097] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
214 Kalva SP, Pectasides M, Liu R, Rachamreddy N, Surakanti S, Yeddula K, Ganguli S, Wicky S, Blaszkowsky LS, Zhu AX. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2014;37:381-387. [PMID: 23754191 DOI: 10.1007/s00270-013-0654-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
215 Labeur TA, Berhane S, Edeline J, Blanc JF, Bettinger D, Meyer T, Van Vugt JLA, Ten Cate DWG, De Man RA, Eskens FALM, Cucchetti A, Bonnett LJ, Van Delden OM, Klümpen HJ, Takkenberg RB, Johnson PJ. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib. Liver Int 2020;40:215-28. [PMID: 31579990 DOI: 10.1111/liv.14270] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
216 Cabibbo G, Maida M, Cammà C, Craxì A. Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age? Expert Rev Anticancer Ther. 2013;13:1355-1361. [PMID: 24224926 DOI: 10.1586/14737140.2013.859989] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
217 Deng Y, Ma H, Tsuneyama K, Yang W, Wang Y, Lu F, Liu C, Liu P, He X, Diehl AM, Gershwin ME, Lian Z. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib. Journal of Autoimmunity 2013;46:25-34. [DOI: 10.1016/j.jaut.2013.07.008] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 5.8] [Reference Citation Analysis]
218 Tovoli F, Dadduzio V, De Lorenzo S, Rimassa L, Masi G, Iavarone M, Marra F, Garajova I, Brizzi MP, Daniele B, Trevisani F, Messina C, Di Clemente F, Pini S, Cabibbo G, Granito A, Rizzato MD, Zagonel V, Brandi G, Pressiani T, Federico P, Vivaldi C, Bergna I, Campani C, Piscaglia F. Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. Liver Cancer 2021;10:370-9. [PMID: 34414124 DOI: 10.1159/000515551] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
219 Chen L, Zheng Y, Zhang H, Pan H, Liu Q, Zhou X, Wei W, Liu Y, Zhen M, Wang J, Zhou J, Zhao Y. Comparative analysis of tumor-associated vascular changes following TACE alone or in combination with sorafenib treatment in HCC: A retrospective study. Oncol Lett 2018;16:3690-8. [PMID: 30127979 DOI: 10.3892/ol.2018.9055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
220 Cappelli A, Cucchetti A, Cabibbo G, Mosconi C, Maida M, Attardo S, Pettinari I, Pinna AD, Golfieri R. Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma. Liver Int. 2016;36:729-736. [PMID: 26604044 DOI: 10.1111/liv.13029] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
221 Brunot A, Le Sourd S, Pracht M, Edeline J. Hepatocellular carcinoma in elderly patients: challenges and solutions. J Hepatocell Carcinoma. 2016;3:9-18. [PMID: 27574587 DOI: 10.2147/jhc.s101448] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
222 Aggarwal A, Ginsburg O, Fojo T. Cancer economics, policy and politics: What informs the debate? Perspectives from the EU, Canada and US. Journal of Cancer Policy 2014;2:1-11. [DOI: 10.1016/j.jcpo.2014.02.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
223 Wang Y, Gou Q, Xu R, Chen X, Zhou Z. Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study. Onco Targets Ther. 2018;11:3407-3413. [PMID: 29928132 DOI: 10.2147/ott.s161023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
224 Nault JC, Pigneur F, Nelson AC, Costentin C, Tselikas L, Katsahian S, Diao G, Laurent A, Mallat A, Duvoux C, Luciani A, Decaens T. Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors. Dig Liver Dis 2015;47:869-76. [PMID: 26211871 DOI: 10.1016/j.dld.2015.07.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
225 Suh SJ, Yim HJ. [Current status of molecular targeted therapies in hepatocellular carcinoma]. Korean J Gastroenterol 2013;61:136-46. [PMID: 23575232 DOI: 10.4166/kjg.2013.61.3.136] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
226 Sommer CM, Stampfl U, Kauczor HU, Pereira PL. [National S3 guidelines on hepatocellular carcinoma]. Radiologe 2014;54:642-53. [PMID: 25047521 DOI: 10.1007/s00117-014-2656-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
227 Sun JY, Yin T, Zhang XY, Lu XJ. Therapeutic advances for patients with intermediate hepatocellular carcinoma. J Cell Physiol 2019;234:12116-21. [PMID: 30648254 DOI: 10.1002/jcp.28019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
228 Dufour JF. Hepatocellular carcinoma: sorafenib: for once age is not an issue. Nat Rev Gastroenterol Hepatol. 2014;11:273-274. [PMID: 24686265 DOI: 10.1038/nrgastro.2014.48] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
229 Branco F, Alencar RS, Volt F, Sartori G, Dode A, Kikuchi L, Tani CM, Chagas AL, Pfiffer T, Hoff P, Carrilho FJ, Alves de Mattos A. The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib. Annals of Hepatology 2017;16:263-8. [DOI: 10.5604/16652681.1231587] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
230 Escudier B, Worden F, Kudo M. Sorafenib: key lessons from over 10 years of experience. Expert Rev Anticancer Ther. 2019;19:177-189. [PMID: 30575405 DOI: 10.1080/14737140.2019.1559058] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
231 Piñero F, Silva M, Iavarone M. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. World J Gastroenterol 2020; 26(16): 1888-1900 [PMID: 32390700 DOI: 10.3748/wjg.v26.i16.1888] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
232 Bolondi L, Craxi A, Trevisani F, Daniele B, Di Costanzo GG, Fagiuoli S, Cammà C, Bruzzi P, Danesi R, Spandonaro F. Refining sorafenib therapy: lessons from clinical practice. Future Oncol. 2015;11:449-465. [PMID: 25360997 DOI: 10.2217/fon.14.261] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
233 Hu FR, Gao F, Qi XS. Linifanib for treatment of hepatocellular carcinoma: An overview of clinical trials. Shijie Huaren Xiaohua Zazhi 2015; 23(16): 2568-2573 [DOI: 10.11569/wcjd.v23.i16.2568] [Reference Citation Analysis]
234 Mukthinuthalapati VVPK, Wang Y, Abu Omar Y, Syed M, Attar B. Single institution experience of sorafenib for advanced HCC in a US tertiary care hospital. J Gastrointest Oncol 2018;9:833-9. [PMID: 30505582 DOI: 10.21037/jgo.2018.06.09] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
235 Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma 2017;4:93-103. [PMID: 28744453 DOI: 10.2147/JHC.S106529] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
236 Cappelli A, Pettinato C, Golfieri R. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. J Hepatocell Carcinoma 2014;1:163-82. [PMID: 27508185 DOI: 10.2147/JHC.S50472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
237 Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Saito T, Motoyama T, Suzuki E, Tawada A, Kanai F, Yokosuka O. Sorafenib treatment in Child–Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs 2015;33:729-39. [DOI: 10.1007/s10637-015-0237-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
238 Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, Tateishi R, Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol. 2017;52:494-503. [PMID: 27549242 DOI: 10.1007/s00535-016-1247-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
239 Granito A, Marinelli S, Negrini G, Menetti S, Benevento F, Bolondi L. Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. Therap Adv Gastroenterol 2016;9:240-9. [PMID: 26929785 DOI: 10.1177/1756283X15618129] [Cited by in Crossref: 43] [Cited by in F6Publishing: 23] [Article Influence: 7.2] [Reference Citation Analysis]
240 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet 2018;391:1301-14. [DOI: 10.1016/s0140-6736(18)30010-2] [Cited by in Crossref: 1580] [Cited by in F6Publishing: 1003] [Article Influence: 395.0] [Reference Citation Analysis]
241 Piñero F, da Fonseca LG. Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups? World J Gastroenterol 2021; 27(24): 3429-3439 [PMID: 34239261 DOI: 10.3748/wjg.v27.i24.3429] [Reference Citation Analysis]
242 Cersosimo RJ. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma. Am J Health Syst Pharm 2021;78:187-202. [PMID: 33211092 DOI: 10.1093/ajhp/zxaa365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
243 Di Marco V, De Vita F, Koskinas J, Semela D, Toniutto P, Verslype C. Sorafenib: from literature to clinical practice. Ann Oncol. 2013;24 Suppl 2:ii30-ii37. [PMID: 23715941 DOI: 10.1093/annonc/mdt055] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
244 Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep 2019;1:17-29. [PMID: 32039350 DOI: 10.1016/j.jhepr.2019.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
245 Zhang HL, Qin XJ, Wang HK, Gu WJ, Ma CG, Shi GH, Zhou LP, Ye DW. Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study. Oncotarget 2015;6:36870-83. [PMID: 26472104 DOI: 10.18632/oncotarget.4874] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
246 Tovoli F, Negrini G, Benevento F, Faggiano C, Goio E, Granito A. Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. Hepat Oncol 2018;5:HEP01. [PMID: 30302192 DOI: 10.2217/hep-2017-0020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
247 Genco C, Cabibbo G, Maida M, Brancatelli G, Galia M, Alessi N, Butera G, Genova C, Romano P, Raineri M. Treatment of hepatocellular carcinoma: present and future. Expert Rev Anticancer Ther. 2013;13:469-479. [PMID: 23560841 DOI: 10.1586/era.13.21] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
248 Nishikawa H, Takeda H, Tsuchiya K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y, Osaki Y, Izumi N; Japanese Red Cross Liver Study Group. Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan. J Cancer 2014;5:499-509. [PMID: 24963354 DOI: 10.7150/jca.9257] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
249 Keating GM. Sorafenib: A Review in Hepatocellular Carcinoma. Target Oncol. 2017;12:243-253. [PMID: 28299600 DOI: 10.1007/s11523-017-0484-7] [Cited by in Crossref: 95] [Cited by in F6Publishing: 107] [Article Influence: 19.0] [Reference Citation Analysis]
250 Mancuso A, Zavaglia C, Bai F, Puoti M, Belli LS. Letter: sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients. Aliment Pharmacol Ther 2013;38:1414-6. [DOI: 10.1111/apt.12536] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
251 Cammà C, Cabibbo G, Petta S, Enea M, Iavarone M, Grieco A, Gasbarrini A, Villa E, Zavaglia C, Bruno R, Colombo M, Craxì A; WEF study group., SOFIA study group. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology 2013;57:1046-54. [PMID: 23299720 DOI: 10.1002/hep.26221] [Cited by in Crossref: 70] [Cited by in F6Publishing: 75] [Article Influence: 7.8] [Reference Citation Analysis]
252 Pelizzaro F, Sammarco A, Dadduzio V, Pastorelli D, Giovanis P, Soldà C, Rizzato MD, Lombardi G, Lonardi S, Peserico G, Imondi A, Sartori A, Maddalo G, Farinati F. Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. Digestive and Liver Disease 2019;51:1713-9. [DOI: 10.1016/j.dld.2019.06.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
253 Kodama K, Kawaoka T, Aikata H, Uchikawa S, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Masaki K, Honda Y, Mori N, Takaki S, Tsuji K, Kohno H, Kohno H, Moriya T, Nonaka M, Hyogo H, Aisaka Y, Chayama K. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. J Gastroenterol Hepatol. 2018;33:1780-1786. [PMID: 29645345 DOI: 10.1111/jgh.14152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
254 Maida M, Cabibbo G, Brancatelli G, Genco C, Alessi N, Genova C, Romano P, Raineri M, Giarratano A, Midiri M. Assessment of treatment response in hepatocellular carcinoma: a review of the literature. Future Oncol. 2013;9:845-854. [PMID: 23718305 DOI: 10.2217/fon.13.33] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
255 Granito A, Marinelli S, Forgione A, Renzulli M, Benevento F, Piscaglia F, Tovoli F. Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. J Hepatocell Carcinoma 2021;8:477-92. [PMID: 34079777 DOI: 10.2147/JHC.S251729] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
256 Bai T, Lei P, Zhou H, Liang R, Zhu R, Wang W, Zhou L, Sun Y. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells. J Cell Mol Med 2019;23:7349-59. [PMID: 31507082 DOI: 10.1111/jcmm.14594] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
257 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 269] [Article Influence: 27.3] [Reference Citation Analysis]
258 Sanduzzi-Zamparelli M, Díaz-Gonzalez Á, Reig M. New Systemic Treatments in Advanced Hepatocellular Carcinoma. Liver Transpl 2019;25:311-22. [PMID: 30317696 DOI: 10.1002/lt.25354] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
259 Golfieri R, Bargellini I, Spreafico C, Trevisani F. Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification. Liver Cancer 2019;8:78-91. [PMID: 31019899 DOI: 10.1159/000489791] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]